Allen Tien, MD, MHS mdlogix.com 94,698 田一彦This is a new hypothesis paper...
This is a new hypothesis paper with an interesting idea about autoimmune disease. These conditions are rising nationwide and globally, and the authors suggest that the endocannabinoid system may be… | Codi Peterson | 10 comments
This is a new hypothesis paper with an interesting idea about autoimmune disease. These conditions are rising nationwide and globally, and the authors suggest that the endocannabinoid system may be playing a bigger part in that problem than we realize. The graphic shows the core idea. When the gut loses important bacteria that produce short chain fatty acids, the gut lining becomes weaker and leakier. That leakiness lets inflammatory signals escape into the bloodstream, and the body responds by making more 2 AG. In small amounts this helps maintain balance. In long term inflammation it can overshoot. The endocannabinoid system begins to downregulate and other systems drift out of balance. High 2 AG for too long can overwhelm the endocannabinoid system. Receptors like CB1, CB2 and TRPV1 start to lose sensitivity, pulling inside the cell instead of staying on the surface where they receive signals. As this happens the gut barrier becomes even looser, systemic inflammation rises, and the cycle accelerates. People with certain genes may be more vulnerable to this pattern. For them the combination of gut dysbiosis, chronic inflammation and endocannabinoid imbalance may help trigger autoimmune conditions or flare ups. This is the proposal from the paper, and the authors emphasize that it is hypothetical. Even so the general idea is useful. An ECS imbalance that begins in the gut may be a shared pathway connecting several autoimmune and inflammatory conditions including type 1 diabetes, Hashimoto’s, Addison’s disease and rheumatoid arthritis. It is not a proven mechanism. It is an early model. But it provides a clearer way to connect the microbiome, gut barrier health, inflammation and the endocannabinoid system. It also helps explain why autoimmune conditions often cluster together and why many of them appear to begin in the gut. SOURCE: Łukowski W. Reframing type 1 diabetes through the endocannabinoidome-microbiota axis: a systems biology perspective. Front Endocrinol (Lausanne). 2025;16:1576419. Published 2025 May 29. doi:10.3389/fendo.2025.1576419 | 10 comments on LinkedIn
